Details of the Drug Combinations

General Information of This Drug (ID: DMR5GSB)

Drug Name

Tetrahydrouridine DMR5GSB

Synonyms

3,4,5,6-Tetrahydrouridine; NSC-112907; NSC 112907; CHEMBL2311128; 18771-50-1; U 23284; NSC-112907-D; BRN 0752319; 2(1H)-pyrimidinone, tetrahydro-4-hydroxy-1-beta-D-ribofuranosyl-; NSC112907; AC1L1H1G; SCHEMBL587704; 3,4,5, 6-Tetrahydrouridine; 2(1H)-Pyrimidinone, tetrahydro-4-hydroxy-1-.beta.-D-ribofuranosyl-; UCKYOOZPSJFJIZ-XVKVHKPRSA-N; MolPort-044-561-340; BDBM50421666; AKOS032953792; DB12484; LS-7719; CS-7633; HY-15345; 3,4,5,6-Tetrahydrouridine (> 80% by HPLC); J-012078

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

6 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Etoposide + Tetrahydrouridine	DCQCB6G	Etoposide	Hodgkin lymphoma (Cell Line: U-HO1)	[2]
PD-0325901 + Tetrahydrouridine	DCFAJ09	PD-0325901	Hodgkin lymphoma (Cell Line: U-HO1)	[3]
PF-562271 + Tetrahydrouridine	DCO71DN	PF-562271	Hodgkin lymphoma (Cell Line: U-HO1)	[2]
Tetrahydrouridine + Idarubicin	DCF6CTY	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
Tetrahydrouridine + Ruxolitinib	DCKK6ZP	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
Tetrahydrouridine + Eltanexor oral	DCL1ZPE	Eltanexor oral	Hodgkin lymphoma (Cell Line: U-HO1)	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
5-Fluoro-2-deoxycytidine + Tetrahydrouridine	DCL80OR	5-Fluoro-2-deoxycytidine	Neoplasms	[4]
5-Fluoro-2-deoxycytidine + Tetrahydrouridine	DCMFHSG	5-Fluoro-2-deoxycytidine	Adult Acute Myeloid Leukemia	[5]
Decitabine + Tetrahydrouridine	DCGYBN7	Decitabine	Metastatic Pancreatic Adenocarcinoma	[6]
Decitabine + Tetrahydrouridine	DCVQGIG	Decitabine	Neoplasm Metastasis	[7]
------------------------------------------------------------------------------------

References

1	Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2007;21(13):1991-7.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4	ClinicalTrials.gov (NCT00359606) 5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer
5	ClinicalTrials.gov (NCT01041443) 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
6	ClinicalTrials.gov (NCT02847000) p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
7	ClinicalTrials.gov (NCT02839694) Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy